News about "Phase 1 clinical trial "

Antengene Advances ATG-201 Autoimmune Programme with Australian Phase I Trial Approval

Antengene’s ATG-201 moves into multinational clinical development after receiving Australian ethics approval and completing the TGA’s CTN process for a Phase I study targeting B cell-related autoimmune diseases.

Phase 1 Clinical Trial | 26/08/2026 | By News Bureau

OncoC4 Doses First Patient in Phase 1 Trial of ONC-783 T-Cell Engager

OncoC4 has dosed the first patient in its Phase 1 ONC-783-001 trial, evaluating the investigational T-cell engager ONC-783, developed to target the cancer-specific neoCD24 epitope in patients with advanced solid tumours.

Phase 1 Clinical Trial | 18/08/2026 | By News Bureau

RiboX Wins FDA IND Clearance for First Circular RNA-Based In Vivo CAR-T Therapy

RiboX Therapeutics receives FDA IND clearance for RXIM002, an investigational circRNA-based in vivo CAR-T therapy designed to generate CD19-targeted CAR-T cells directly inside the body for autoimmune cytopenias.

Phase 1 Clinical Trial | 10/08/2026 | By News Bureau

Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013

Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.

Phase 1 Clinical Trial | 27/07/2026 | By News Bureau |  110

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of Japanese Cedar Allergy Vaccine

Immunomic Therapeutics has initiated Phase 1 clinical testing of ITI-9001 after dosing the first participant in Japan, advancing the development of a next-generation therapeutic vaccine for Japanese cedar pollen allergy.

Phase 1 Clinical Trial | 06/07/2026 | By News Bureau |  103

Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27

The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.

Phase 1 Clinical Trial | 08/05/2026 | By News Bureau |  218

Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118

Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.

Phase 1 Clinical Trial | 05/05/2026 | By News Bureau |  290

MetaVia Advances Obesity Drug Development with First Patient Dosed in DA-1726 Phase I Trial

MetaVia initiates Part 3 of its phase I trial for DA-1726, evaluating higher-dose strategies to enhance weight loss, metabolic outcomes and tolerability in obesity and cardiometabolic disease treatment.

Phase 1 Clinical Trial | 13/04/2026 | By News Bureau |  124

Phrontline Biopharma Announces First Patient Dosed in Phase-I Clinical Trial of TJ101

The Phase 1 study of TJ101 will assess its safety, tolerability, pharmacokinetics, and early anti-tumor activity in various solid tumors, using a dose escalation and expansion cohort design.

Phase 1 Clinical Trial | 15/09/2025 | By Dineshwori |  209

Inventiva and Hepalys Pharma Initiate Clinical Development Program of Lanifibranor in Japan

The trial is conducted pursuant to the terms of the exclusive licensing agreement entered into in 2023 between Inventiva and Hepalys to develop and commercialize lanifibranor in Japan and South Korea.

Phase 1 Clinical Trial | 21/02/2025 | By Aishwarya |  762